Business context and reporting period
The supplied metadata names Standard BioTools Inc., but the filing identifies the registrant as Fluidigm Corporation. This is Fluidigm’s Form 10-K for the fiscal year ended December 31, 2014; fourth-quarter figures are also reported. Fluidigm sells life-science research instruments and consumables focused on single-cell genomics and proteomics and applied genomics. It completed its acquisition of DVS Sciences on February 13, 2014.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $116.5 million | $71.2 million |
| Product revenue | $115.9 million | $70.2 million |
| Operating loss | $51.8 million | $18.7 million |
| Net loss | $52.8 million | $16.5 million |
| Net loss per share, diluted | $1.90 | $0.65 |
| Product margin | 63% | 71% |
| Operating cash flow | $(22.6) million | $(1.6) million |
Fourth-quarter 2014 revenue was $33.5 million, net loss was $10.9 million, and diluted loss per share was $0.39. Revenue was up 64% for the year, including $20.7 million from DVS after acquisition. Excluding acquisition-related amortization and inventory fair-value charges, management said product margins improved by one percentage point year over year; reported margin fell partly because those charges and a shift in mix toward lower-margin instruments weighed on results.
At year-end, cash and cash equivalents were $33.7 million and short- and long-term investments totaled $109.1 million. Working capital, excluding deferred revenue, was $133.4 million. Convertible notes had $201.3 million principal outstanding and a $195.5 million carrying value; the notes bear 2.75% interest and mature in 2034, subject to conversion, redemption, and repurchase terms. The company reported total assets of $407.6 million and stockholders’ equity of $150.4 million.
Material changes versus prior period
- Revenue growth reflected higher instrument and consumables sales, the DVS acquisition, and continued expansion of Fluidigm’s genomics business. Excluding acquired CyTOF revenue, instrument revenue grew 30% and consumables revenue grew 44%.
- Operating expenses rose substantially: research and development increased to $43.4 million from $20.0 million, and selling, general and administrative expense rose to $71.3 million from $48.4 million. Acquisition-related expense was $10.7 million.
- Product margin declined from 71% to 63%, including about nine percentage points of 2014 margin impact primarily from acquired-intangible amortization and inventory fair-value write-up.
- Cash used in operations increased to $22.6 million. Investing cash use of $178.4 million included the DVS acquisition and investment purchases; financing cash inflow of $200.3 million was primarily net proceeds from the convertible-note offering.
- Total assets increased from $116.9 million to $407.6 million, principally reflecting acquisition-related goodwill and developed technology. Accumulated deficit reached $310.2 million.
Outlook, commentary, risks and unusual items
- Management expected existing cash, cash equivalents, and investments to fund working capital and capital expenditures for at least 18 months, while noting that additional capital could be needed depending on operating performance, investment needs, or acquisitions.
- Management expected research and development and selling, general and administrative expenses to increase. It also expected unfavorable foreign-exchange trends to weigh on 2015 revenue; exchange rates reduced fourth-quarter 2014 revenue by approximately 3%.
- Planned or recently announced products included Juno, expected in the first quarter of 2015, and Callisto, Polaris, and a high-throughput C1 sequencing IFC, each expected around mid-2015. Commercial timing and customer acceptance were uncertain.
- Key risks include continuing losses and negative operating cash flow; early-stage and evolving target markets; competition and lengthy sales cycles; reliance on sole- or limited-source suppliers and concentrated manufacturing facilities; and potential product-development, yield, or supply interruptions.
- A material intellectual-property uncertainty concerned the PerkinElmer mass-cytometry license: PerkinElmer asserted that the DVS acquisition required its consent and negotiation of a commercially reasonable license. Fluidigm said it was seeking discussions and evaluating its options.
- Products were labeled for research use only. FDA guidance on research-use products and draft guidance on laboratory-developed tests could affect customer use, sales, or regulatory obligations. The filing also noted domestic-manufacturing obligations associated with certain government-funded licensed technology and a pending waiver request.
- Unusual 2014 items included $10.7 million of acquisition-related expense, $9.8 million of acquired-technology amortization, and a $4.9 million income-tax benefit, primarily associated with acquisition-related deferred taxes and a release of a California valuation allowance. The benefit reduced, but did not eliminate, the net loss.
Important facts for investors to verify
- Confirm the issuer’s identity and corporate-name relationship: the provided metadata says Standard BioTools Inc., while this filing names Fluidigm Corporation.
- Track subsequent outcomes of the PerkinElmer license negotiations and any related consent, royalty, or product-rights changes.
- Assess whether the acquired DVS business and planned product launches deliver sustained revenue growth, customer adoption, and improving margins.
- Monitor operating cash use, liquidity runway, and the terms and potential dilution or cash obligations associated with the convertible notes.
- Check whether currency headwinds, acquisition-related charges, and increased operating expenses continue to affect results.